文献速递临床试验与 GCP真实世界研究与卫生经济

高容量血液透析滤过与高通量血液透析登记试验(H4RT):一项多中心、非盲、随机、平行组、优效性研究,利用常规医疗数据库关联结局比较高容量血液透析滤过与高通量血液透析在维持性透析肾衰竭患者中的有效性和成本效益

The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): a multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes.
PubMed 文献 · Trials · 2022-06-27

H4RT是一项英国多中心、非盲、随机、平行组、优效性试验,拟将已接受血液透析或血液透析滤过的成年肾衰竭患者按1:1随机分配至高容量血液透析滤过(目标置换液量21 L以上,按体表面积调整)或高通量血液透析。主要结局为随访期间(最短32个月,最长91个月)非癌症死亡或心血管事件或感染住院的复合终点,通过常规数据确定。研究将提供两种透析方式的有效性和成本效益证据。

要点

  • 高容量血液透析滤过目标置换液量21 L以上,按体表面积调整。
  • 主要结局为随访期间非癌症死亡或心血管事件或感染住院的复合终点。
  • 随访通过关联常规医疗数据库和中心管理的患者问卷收集数据。

核心结论

  • 本研究将提供高容量血液透析滤过与高通量血液透析相比在成年中心血液透析或血液透析滤过肾衰竭患者中的有效性和成本效益证据。
  • 研究结果将为英国及国际上该患者群体的管理提供信息。

研究设计与样本

  • 英国多中心、非盲、随机、平行组、优效性试验。
  • 已接受血液透析或血液透析滤过的成年患者按1:1随机分配至高容量血液透析滤过或高通量血液透析。
  • 高容量血液透析滤过目标为置换液量21 L以上,按体表面积调整。
  • 排除标准包括无同意能力、预期寿命小于3个月、接受血液透析或血液透析滤过少于4周、计划3个月内活体肾移植或家庭透析、既往对血液透析滤过不耐受以及因其他临床原因不适合高容量血液透析滤过。
  • 主要结局为随访期间(最短32个月,最长91个月)非癌症死亡或心血管事件或感染住院的复合终点,通过常规数据确定。

关键数值与推荐

  • 主要结局为随访期间非癌症死亡或心血管事件或感染住院的复合终点,随访最短32个月,最长91个月。
  • 次要结局包括全因死亡、心血管和感染相关发病率和死亡率、健康相关生活质量、成本效益和环境影向。
  • 随访数据通过关联常规医疗数据库(英格兰的医院统计、民事登记、英格兰公共卫生和英国肾脏登记处,以及苏格兰和威尔士的等效数据库)和中心管理的患者填写问卷收集。
  • 研究现场人员监测不良事件并收集方案依从性数据(招募期间每月一次,随访期间每季度一次)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More than a third of the 65,000 people living with kidney failure in the UK attend a dialysis unit 2-5 times a week to have their blood cleaned for 3-5 h. In haemodialysis (HD), toxins are removed by diffusion, which can be enhanced using a high-flux dialyser. This can be augmented with convection, as occurs in haemodiafiltration (HDF), and improved outcomes have been reported in people who are able to achieve high volumes of convection. This study compares the clinical- and cost-effectiveness of high-volume HDF compared with high-flux HD in the treatment of kidney failure. METHODS: This is a UK-based, multi-centre, non-blinded randomised controlled trial. Adult patients already receiving HD or HDF will be randomised 1:1 to high-volume HDF (aiming for 21+ L of substitution fluid adjusted for body surface area) or high-flux HD. Exclusion criteria include lack of capacity to consent, life expectancy less than 3 months, on HD/HDF for less than 4 weeks, planned living kidney donor transplant or home dialysis scheduled within 3 months, prior intolerance of HDF and not suitable for high-volume HDF for other clinical reasons. The primary outcome is a composite of non-cancer mortality or hospital admission with a cardiovascular event or infection during follow-up (minimum 32 months, maximum 91 months) determined from routine data. Secondary outcomes include all-cause mortality, cardiovascular- and infection-related morbidity and mortality, health-related quality of life, cost-effectiveness and environmental impact. Baseline data will be collected by research personnel on-site. Follow-up data will be collected by linkage to routine healthcare databases - Hospital Episode Statistics, Civil Registration, Public Health England and the UK Renal Registry (UKRR) in England, and equivalent databases in Scotland and Wales, as necessary - and centrally administered patient-completed questionnaires. In addition, research personnel on-site will monitor for adverse events and collect data on adherence to the protocol (monthly during recruitment and quarterly during follow-up). DISCUSSION: This study will provide evidence of the effectiveness and cost-effectiveness of HD as compared to HDF for adults with kidney failure in-centre HD or HDF. It will inform management for this patient group in the UK and internationally. TRIAL REGISTRATION: ISRCTN10997319 . Registered on 10 October 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Caskey FJ, Procter S, MacNeill SJ, et al. The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): a multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes. Trials. 2022. PMID: 35761367. doi:10.1186/s13063-022-06357-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。